CAR T Cell Therapy for Glioblastoma - Division of Neuro Oncology, Stanford Medicine

The Stanford Brain Tumor Center adopts a collaborative approach to the treatment of brain and spine tumors, with specialists developing comprehensive treatment strategies and provide ongoing support to patients throughout their journey. Additionally, the center boasts an innovative research program spanning basic, translational, and clinical research.

One key research initiative revolves around the utilization of CAR T cell immunotherapy to combat glioblastoma, an aggressive form of brain tumor. With approximately 12,000 new diagnoses of GBM annually in the United States and a disheartening five-year survival rate of less than 10%, innovative approaches are urgently needed.

Led by Dr. Reena Thomas, MD, PhD, the B7H3 CAR T clinical trial aims to harness a patient's own T cells to selectively target and eliminate cancer cells, while preserving the integrity of surrounding healthy brain tissue. If successful, this pioneering form of precision medicine holds the potential to revolutionize the treatment landscape for this lethal brain tumor.